# Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy

Source: https://onco.cc/trials/nct07506057/  
OnCo record `nct07506057` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trastuzumab and serplulimab in gallbladder cancer and other biliary tract cancers, run by Xiujuan Qu, now recruiting.

## Summary

Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy is a phase 2 interventional study registered as NCT07506057 by Xiujuan Qu, with a registry enrolment figure of 20 participants, started 2025-07-15 and due to reach its primary completion in 2027-07. Interventions recorded: Trastuzumab+Serplulimab. Conditions listed: Urothelial Carcinoma, Biliary Tract Cancer, HER2. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SHIELD
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07506057
- Phase: 2
- Setting: An Open-label, Single-arm Phase II Clinical Study of Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
- Sponsor: Xiujuan Qu
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07506057: https://clinicaltrials.gov/study/NCT07506057

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07506057.json